If you search "what is SLU-PP-332", most of what comes back files it under peptides and talks about vials, reconstitution and endurance. Two of those three things are wrong. SLU-PP-332 is a small molecule — a synthetic pan-agonist of the estrogen-related receptors ERRα, ERRβ and ERRγ — with no amino acids and no peptide bonds in it. And the endurance data everyone quotes comes from mice.

But the more interesting story in the 2026 SLU-PP-332 research isn't the mouse treadmill result. It's that the chemists who built the molecule have spent the last eighteen months publishing papers about how to replace it.

SLU-PP-332 was a tool compound, not a drug candidate

In medicinal chemistry, a "tool compound" is a molecule good enough to prove that hitting a target does something interesting. It doesn't have to survive the gut, last in plasma, or be selective enough for chronic human dosing. It just has to answer the question.

SLU-PP-332 answered its question well. It activates ERRs in the low-to-mid nanomolar range, switches on an oxidative gene program in skeletal muscle, and in the 2024 Journal of Pharmacology and Experimental Therapeutics paper it increased energy expenditure and fatty acid oxidation and reduced fat mass accumulation in diet-induced obese and ob/ob mice — administered by intraperitoneal injection, because that was the only way to get useful exposure.

That last detail is the whole story. The compound circulating in the research-chemical market is the version that needed a needle to work in a mouse.

The 2026 papers are all about fixing its liabilities

Three separate lines of published work in the past year treat SLU-PP-332 as a starting point rather than an endpoint:

SLU-PP-915: the oral successor

In January 2026, the same research group published SLU-PP-915 in JPET — described as the first orally bioavailable pan-ERR agonist. The framing in the paper is explicit: SLU-PP-332 improves aerobic performance in mice but lacks oral bioavailability. SLU-PP-915 matched it by injection and held up when given by mouth, with roughly 50% improvements in treadmill running distance and time versus vehicle controls. Still mice. Still no humans. But it exists because 332's pharmacokinetics were the bottleneck.

The structure–activity paper: solubility and metabolic stability

In April 2026, a group at Washington University in St Louis with collaborators at the University of Florida published the first comprehensive structure–activity relationship study of the SLU-PP-332 scaffold in the International Journal of Biological Macromolecules. Their conclusion is measured and useful: 332 remains a strong benchmark for ERR activation, but several analogues achieve comparable transcriptional responses with better ligand efficiency, solubility or metabolic stability. Translation — the original scaffold has real drug-likeness problems, and the field is enumerating them.

The anti-doping chemistry

Separately, two 2026 analytical papers characterised the in vitro metabolites of SLU-PP-332 (and 915) specifically so sports labs can detect them — a metabolism and characterisation study covering both compounds appeared this year. Detection infrastructure now exists for a compound that has never been given to a human in a registered trial.

What this means for anyone reading SLU-PP-332 claims

A tool compound isn't a failed compound. But it does change how you should read marketing copy:

  • Dose translation is meaningless. There is no human pharmacokinetic data. Milligram figures circulating online are not derived from any human exposure study; they are back-of-envelope conversions from mouse mg/kg doses given by a route nobody is using.
  • "Oral SLU-PP-332" is a contradiction. Poor oral bioavailability is the documented reason 915 was made. If a product claims oral activity for 332, the published literature is against it.
  • Pan-agonism is broad. ERRα, β and γ sit upstream of a large transcriptional program across muscle, heart, liver and brown fat. The SAR paper's interest in selectivity is a signal that "activate all three, systemically, for months" is not a solved safety question.
  • It is not a peptide. That matters beyond pedantry — handling, stability and purity-testing assumptions borrowed from peptide content simply don't transfer. We cover the full profile on our SLU-PP-332 page and the broader peptides index.

Is SLU-PP-332 legal in Australia? The regulatory position

SLU-PP-332 does not appear in the Poisons Standard by name. People sometimes point to the SR9009 entry as covering it — that entry concerns REV-ERB agonists, a different receptor family and a different chemical class. Being unscheduled is not permission: SLU-PP-332 has no entry in the Australian Register of Therapeutic Goods, no approved indication and no lawful therapeutic supply pathway here. Anything supplied for human use falls under the TGA's unapproved therapeutic goods framework, and "research use only" labelling on a vial doesn't change what happens if it goes into a person.

For athletes, the position is simpler and stricter. WADA's S0 catch-all prohibits substances with no current approval by any government regulatory health authority for human therapeutic use — which is exactly what SLU-PP-332 is. Sport Integrity Australia applies the WADA list domestically. With 2026 detection methods now published, "undetectable" is no longer even an argument.

One more caution for anyone checking primary sources: if you find a human trial listing for SLU-PP-332 on a registry, check the sponsor is a real, verifiable organisation before you believe it. Demonstration and placeholder records for fashionable compounds do circulate.

The honest summary

SLU-PP-332 is a genuinely interesting piece of pharmacology with a real mechanism and real mouse data behind it. It is also, on the published record, the prototype — the molecule its own field is actively engineering past. That's a normal, healthy stage of drug discovery. It's just not the stage at which anything should be going into a person.

Want the evidence updates without the hype? Join the free list.

FAQ

Is SLU-PP-332 a peptide?

No. SLU-PP-332 is a synthetic small molecule that activates the estrogen-related receptors ERRα, ERRβ and ERRγ. It contains no amino acid chain, so the common "peptide" label is a category error.

Is SLU-PP-332 legal in Australia?

It is not named in the Poisons Standard, but it has no ARTG registration and no lawful therapeutic supply pathway in Australia. It is also prohibited in sport at all times under WADA's S0 catch-all category.

What is the difference between SLU-PP-332 and SLU-PP-915?

Both are pan-ERR agonists from the same research program. SLU-PP-915, published in January 2026, was developed because SLU-PP-332 is not orally bioavailable; 915 showed comparable mouse exercise-capacity effects when given by mouth.

Does SLU-PP-332 work in humans?

Unknown. Every efficacy result to date is from mice, and there are no completed or registered human trials, so there is no human safety, dosing or effectiveness data at all.

Sources

This article is general information, not medical advice. SLU-PP-332 is an investigational research compound with no human trials and no approval from the TGA, FDA or any other regulator. retatrutide.net.au is independent and does not sell or source compounds.